Irinotecan Onkovis (Irinotecan Hydrochloride Trihydrate)

Irinotecan is a pro‑drug that is converted inside cells to the active metabolite SN‑38. SN‑38 binds to the DNA‑topoisomerase I complex, preventing the re‑ligation of single‑strand DNA breaks that occur during replication. This leads to accumulation of DNA damage, replication arrest, and ultimately apoptosis of rapidly dividing cancer cells.

The dosing regimen for Irinotecan Onkovis is individualized by the prescribing oncologist based on factors such as the patient’s weight, disease stage, treatment protocol, and renal or hepatic function. Specific dose amounts and infusion schedules should be determined by a qualified healthcare professional.

Safety data for Irinotecan use in pregnancy or while breastfeeding are limited. Because the drug may pose risks to the fetus or infant, it is generally avoided unless the potential benefit justifies the potential harm. Patients should discuss reproductive plans with their physician before starting therapy.

To order Irinotecan Onkovis, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, and will request verification of trade or institutional credentials. The sales team then provides pricing, availability, shipping details (including cold‑chain handling if needed) and assists with import documentation.

Irinotecan belongs to the topoisomerase I inhibitor class and is often used when disease has progressed after fluoropyrimidine‑based regimens. Compared with agents such as oxaliplatin, irinotecan offers a different mechanism of action and toxicity profile, making it a valuable option in combination protocols or as a second‑line therapy for metastatic colorectal cancer.

Irinotecan Onkovis should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking. Before administration, allow the product to reach room temperature if required, and follow aseptic techniques for preparation and infusion.

Irinotecan Onkovis is given by intravenous infusion, usually over 30 to 90 minutes depending on the treatment protocol. The infusion is performed in a clinical setting by qualified healthcare personnel, with monitoring for infusion‑related reactions and supportive care measures such as anti‑emetics and hydration as needed.

The most serious adverse events include severe neutropenia, febrile neutropenia, life‑threatening diarrhea (often referred to as irinotecan‑induced colitis), cholinergic syndrome, and rare allergic reactions such as anaphylaxis. Prompt recognition and medical intervention are essential to manage these potentially life‑threatening conditions.

Irinotecan Onkovis is contraindicated in patients with known hypersensitivity to irinotecan or any of its excipients, and in individuals with severe hepatic impairment where drug clearance is markedly reduced. Caution is also advised for patients with pre‑existing bone‑marrow suppression or uncontrolled infections.